Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Transatlantic Exchange: Joint Interview with Dr. Toni Choueiri (Dana-Farber) and Prof. Karim Fizazi (Gustave Roussy)
On 19 March, the 4th edition of the Transatlantic Exchanges took place in Paris—a scientific day co-organised by Gustave Roussy and the Dana-Farber Cancer Institute with support from the Servier Institute. Dr. Toni Choueiri (Dana-Farber) and Prof. Karim Fizazi (Gustave Roussy), co-chairs of the event, reflect on the key themes of this edition, dedicated to radiopharmaceutical therapies.
Published on
On 19 March, the 4th edition of the Transatlantic Exchanges took place in Paris—a scientific day co-organised by Gustave Roussy and the Dana-Farber Cancer Institute with support from the Servier Institute. Dr. Toni Choueiri (Dana-Farber) and Prof. Karim Fizazi (Gustave Roussy), co-chairs of the event, reflect on the key themes of this edition, dedicated to radiopharmaceutical therapies.
Why did you choose radiopharmaceutical therapies as this year’s theme?
Dr. Toni Choueiri: This field is progressing rapidly, with many treatments currently under development. Yet, the clinical steps leading to a new radiopharmaceutical are still not fully understood by many physicians and researchers. This meeting between our two institutions is, therefore, a unique opportunity to gain a deeper understanding of this issue.
Prof. Karim Fizazi: Both Gustave Roussy and Dana-Farber are heavily invested in this field. The event provided an opportunity to present promising research on PSMA targeting, notably used in the treatment of prostate cancer. It is a therapeutic approach that is set to keep evolving.
Dr. Toni Choueiri: Absolutely. And interesting prospects are emerging in other cancers, such as breast cancer. We are also seeing the growing use of antibody-drug conjugates, which might eventually be combined with radioisotopes. For that, close collaboration with physicists and chemists is essential.
How does the partnership between Gustave Roussy and Dana-Farber take shape throughout the year?
Prof. Karim Fizazi: Beyond this annual event, we conduct scientific exchanges all year long. We send young talents from Gustave Roussy—doctors, pharmacists, researchers—to Boston to strengthen their expertise. Some are currently working in Toni’s lab. This program serves as a genuine springboard, and we hope it will soon become reciprocal.
Dr. Toni Choueiri: I hope so too. We have already received many applications from people keen to come to Paris.
On what subject will the next edition of the Transatlantic Exchanges focus on?
Dr. Toni Choueiri: Following this fourth edition, we will regroup to plan the fifth meeting, which will take place next year in Boston.
Prof. Karim Fizazi: A few years ago, therapeutic options in oncology were limited to chemotherapy and radiotherapy. Today, they have expanded to targeted therapies, immunotherapy, CAR-T cells... There are still many topics to explore.
Why are events like this so important to the scientific community?
Dr. Toni Choueiri: These meetings are essential. Even though the ocean separates us, we share the same core values: care, research, teaching, and innovation. The Transatlantic Exchanges strengthen our ties.
Prof. Karim Fizazi: Each edition provides the opportunity to address a key issue in oncology—this year, radiopharmaceuticals, previously AI, immunotherapy or liquid biopsy. These exchanges foster new ideas and improve patient care. It is a valuable collaboration between France and the United States.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
